Inmune Bio, Inc. (NASDAQ: INMB)

Sector: Healthcare Industry: Biotechnology CIK: 0001711754
Market Cap 32.94 Mn
P/B 1.30
P/E -0.66
P/S 658.88
ROIC (Qtr) -184.22
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 1.08 Mn
Debt/Equity (Qtr) 0.04
Add ratio to table...

About

Inmune Bio, Inc., a prominent player in the biotechnology industry, is dedicated to the development and commercialization of groundbreaking therapies that target the innate immune system to address various diseases such as cancer, Alzheimer's disease, and treatment-resistant depression. The company's primary product candidates include INKmune, INB03, and XPro, all designed to neutralize soluble tumor necrosis factor (sTNF) and modulate the immune response to treat cancer and other diseases. Inmune Bio's main business activities revolve around the...

Read more

Investment thesis

Bull case

  • Healthy cash reserves of 27.73M provide 60.69x coverage of short-term debt 457000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 33.36M provides 30.89x coverage of total debt 1.08M, indicating robust asset backing and low credit risk.
  • Cash reserves of 27.73M provide robust 3.77x coverage of current liabilities 7.36M, indicating strong short-term solvency.
  • Cash position of 27.73M represents healthy 1.19x of working capital 23.31M, demonstrating strong operational liquidity.
  • Robust R&D investment of 25.68M at 2.78x of SG&A 9.23M demonstrates strong commitment to innovation and future growth.

Bear case

  • Investment activities of (193000) provide weak support for R&D spending of 25.68M, which is -0.01x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (30.65M) shows concerning coverage of stock compensation expenses of 8.35M, with a -3.67 ratio indicating potential earnings quality issues.
  • Free cash flow of (30.84M) provides weak coverage of capital expenditures of 193000, with a -159.81 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (49.89M) show weak coverage of depreciation charges of 28000, with a -1781.68 ratio indicating high capital intensity and potential reinvestment needs.
  • Operating cash flow of (30.65M) barely covers operating expenses of 16.51M with a -1.86 ratio, suggesting thin operational efficiency margins and limited flexibility.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.00 11.06
EV to Cash from Ops. EV/CFO 0.00 26.32
EV to Debt EV to Debt 0.02 762.61
EV to EBIT EV/EBIT 0.00 -13.49
EV to EBITDA EV/EBITDA 0.00 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF 0.00 25.66
EV to Market Cap EV to Market Cap 0.00 203.37
EV to Revenue EV/Rev 0.42 156.31
Price to Book Value [P/B] P/B 1.30 20.59
Price to Earnings [P/E] P/E -0.66 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Interest Coverage 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -17.34 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -20.87 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -23.59 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -20.87 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -20.87 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 2.75 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -19.79 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 19.05 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 3.77 3.92
Current Ratio Curr Ratio (Qtr) 4.17 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.04 0.48
Interest Cover Ratio Interest Cover Ratio 0.00 956.66
Times Interest Earned Times Interest Earned 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -99,718.00 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -99,774.00 -18,246.34
EBT Margin % EBT Margin % (Qtr) -99,774.00 -19,108.08
Gross Margin % Gross Margin % (Qtr) 100.00 -10.30
Net Profit Margin % Net Margin % (Qtr) -99,774.00 -19,056.96